表达新型TEL-PDGFRB嵌合体的慢性特发性骨髓纤维化对甲磺酸伊马替尼治疗有反应。 - Suppr

Suppr

超能文献

Chronic idiopathic myelofibrosis expressing a novel type of TEL-PDGFRB chimaera responded to imatinib mesylate therapy.

作者信息

Tokita K, Maki K, Tadokoro J, Nakamura Y, Arai Y, Sasaki K, Eguchi-Ishimae M, Eguchi M, Mitani K

出版信息

Leukemia. 2007 Jan;21(1):190-2. doi: 10.1038/sj.leu.2404397. Epub 2006 Nov 23.

DOI:10.1038/sj.leu.2404397

PMID:17122866

Abstract

摘要

相似文献

Chronic idiopathic myelofibrosis expressing a novel type of TEL-PDGFRB chimaera responded to imatinib mesylate therapy.

Leukemia. 2007 Jan;21(1):190-2. doi: 10.1038/sj.leu.2404397. Epub 2006 Nov 23.

Lack of response to imatinib mesylate in a patient with accelerated phase myeloproliferative disorder with rearrangement of the platelet-derived growth factor receptor beta-gene.

Haematologica. 2004 Oct;89(10):1263-4.

Trisomy 8 in PDGFRB-negative cells in a patient with imatinib-sensitive chronic myelomonocytic leukemia and t(5;16)(q33;p13), PDGFRB-NDE1 fusion.

Cancer Genet Cytogenet. 2009 Oct;194(1):67-9. doi: 10.1016/j.cancergencyto.2009.04.026.

Development of AML with t(8;21)(q22;q22) and RUNX1-RUNX1T1 fusion following Philadelphia-negative clonal evolution during treatment of CML with Imatinib.

Cancer Genet Cytogenet. 2009 Feb;189(1):63-7. doi: 10.1016/j.cancergencyto.2008.09.016.

Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.

N Engl J Med. 2002 Aug 15;347(7):481-7. doi: 10.1056/NEJMoa020150.

Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.

Cancer. 2003 Jun 1;97(11):2760-6. doi: 10.1002/cncr.11416.

Molecular diagnosis and targeted therapy of a pediatric chronic eosinophilic leukemia patient carrying TPM3-PDGFRB fusion.

Pediatr Blood Cancer. 2011 Mar;56(3):463-6. doi: 10.1002/pbc.22800.

KANK1, a candidate tumor suppressor gene, is fused to PDGFRB in an imatinib-responsive myeloid neoplasm with severe thrombocythemia.

Leukemia. 2010 May;24(5):1052-5. doi: 10.1038/leu.2010.13. Epub 2010 Feb 18.

Myelofibrosis with a novel translocation, t(1;3)(q31;q23), and response to imatinib mesylate.

Leukemia. 2007 Mar;21(3):577-8. doi: 10.1038/sj.leu.2404552. Epub 2007 Jan 18.

A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylate.

Leuk Res. 2004 May;28 Suppl 1:S65-9. doi: 10.1016/j.leukres.2003.10.011.

引用本文的文献

A Case of Acute Myeloid Leukemia Harboring a Rare Three-Way Translocation t(5;7;7) Involving the Gene and Successfully Treated with Imatinib.

Cancer Manag Res. 2021 Nov 25;13:8841-8847. doi: 10.2147/CMAR.S324718. eCollection 2021.

T cell acute lymphoblastic lymphoma complicated with myeloid sarcoma in an adult: A case report.

Oncol Lett. 2017 Dec;14(6):8178-8182. doi: 10.3892/ol.2017.7187. Epub 2017 Oct 16.

PDGFRᵝ-Rearranged Myeloid Neoplasm with Marked Eosinophilia in a 37-Year-Old Man; And a Literature Review.

Am J Case Rep. 2017 Feb 17;18:173-180. doi: 10.12659/ajcr.900623.

Marked response to imatinib mesylate in a patient with platelet-derived growth factor receptor beta-associated acute myeloid leukemia.

Int J Hematol. 2017 May;105(5):697-701. doi: 10.1007/s12185-016-2167-z. Epub 2016 Dec 20.

Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib.

Blood. 2014 Jun 5;123(23):3574-7. doi: 10.1182/blood-2014-02-555607. Epub 2014 Mar 31.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验